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Abstract: Multiple sclerosis is a chronic disease characterized by demyelination and 
neurodegeneration of the central nervous system. Immunomodulatory treatment is possible at 
an early stage of the disease, and consists of injections of either beta-interferon or glatiramer 
acetate. The drugs are not curative, and the need for frequent injections may give rise to a 
serious problem regarding adherence to treatment. The present study analyzed the database 
of all Brazilian patients using glatiramer acetate between June 2003 and December 2006 who 
had enrolled in the patient program run by the pharmaceutical company commercializing the 
drug. The rate of treatment discontinuation was 10% over this period, and the main reason 
for suspending the drug was medical decisions (47% of all discontinuations), rather than side 
effects or the patient’s choice. The present work did not take into consideration the regularity of 
injections and the main objective was to assess discontinuation. It was concluded that adequate 
healthcare, education, and a speciﬁ  c program for patients were the factors responsible for this 
90% adherence to glatiramer acetate treatment in Brazil.
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Introduction
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS). 
Although inﬂ  ammation and demyelination are the pathological hallmark of MS, the 
associated neurodegeneration leads to neurological sequelae, which makes MS the 
second greatest cause of neurological disability among young adults, surpassed only 
by trauma.
The most typical and frequent presentation of the disease is the remitting-relapsing 
form, characterized by bouts of neurological signs and symptoms lasting from a few 
weeks to a few months and longer periods of clinical remission. Despite decades of 
intense research on the causes of and cures for MS, there are still vast knowledge gaps 
regarding this condition.
Apart from symptomatic treatment that should be proposed for all patients with 
MS, some patients also qualify for immunomodulatory and/or immunosuppressive 
treatment. These qualifying patients are those at the early, mainly inﬂ  ammatory phase 
of the disease, when relapses are still frequent and are related to T1-lymphocytes and 
other immunological cells targeting the CNS. The immunomodulatory treatment at 
this stage may be performed by means of either beta-interferon (IFNβ) in three dif-
ferent formulations, or glatiramer acetate (GA). All of these treatments are in the 
form of injections: IFNβ subcutaneously or intramuscularly, and GA subcutaneously. 
More recently, monoclonal antibodies have been introduced as a possible form of 
treatment, but drugs at present approved in most countries are still IFNβ and GA. These 
medications, many of which have the possibility for self-injection, have a variety of 
side effects, including reactions at the injection site among those used subcutaneously. 
It is important to emphasize that these drugs must be used over a very long period of Patient Preferences and Adherence 2008:2 42
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time, and their effect is to reduce the frequency of relapses, 
which is not always an easy target to assess from the point 
of view of the patients, who may have much higher expecta-
tions from MS treatment.
Patient adherence to such treatments needs to be care-
fully assessed. According to the World Health Organiza-
tion (2003), adherence is deﬁ  ned as the extent to which 
the behavior of an individual undergoing treatment really 
corresponds to the recommendations given by the healthcare 
professional. A variety of factors may inﬂ  uence adherence 
in MS cases, and a list of such factors, far from complete, 
is presented in Table 1. Few studies have been performed 
to assess the reasons for withdrawing from treatment with 
IFNβ (Hadjimichael and Vollmer 1999; Tremlett and Orger 
2003; Rio et al 2005) and even fewer in relation to GA 
(Fraser et al 2001).
The ﬁ  rst 6 months of treatment seem to be crucial for 
proper adherence (Tremlett and Orger 2003), and side 
effects during this period appear to be the main reason for 
withdrawal of injections (O’Rourke and Hutchinson 2005). 
Starting therapy in very disabled patients also seems to lead to 
higher degrees of non-adherence (Rio et al 2005). Healthcare 
support for patients has been rated as an important factor in 
adherence, particularly for patients who were already switch-
ing between immunomodulatory drugs (Fraser et al 2001).
The aim of the present study was to assess the level of 
adherence and discontinuation of therapy with GA among 
Brazilian patients who have had access to a special pro-
gram developed by TEVA Pharmaceutical speciﬁ  cally for 
Brazil. Unlike the programs proposed by TEVA and other 
pharmaceutical companies in other countries, the Brazilian 
program does not consider patients to be at “high” or “low” 
risk of discontinuation and, once enrolled in the personal 
assistance program, all patients receive the same care.
The Brazilian Federal and State governments provide the 
drugs freely to all patients with MS who require immuno-
modulatory treatment. Patients who receive a diagnosis of 
MS are referred to the closest university reference center for 
investigation and treatment of the disease, with a prescrip-
tion for a particular immunomodulatory drug given by the 
neurologist accompanying the case. Should the reference 
center conﬁ  rm the diagnosis and the precise indication for 
this prescription, the patient will receive the medication 
monthly, free of any charge. In the MS Reference Center 
for the coastal region of the State of São Paulo (Fragoso and 
Fiore 2005), all patients learn directly from the nurse how to 
perform the injections. The nurse also provides them with 
her personal telephone numbers for any contact that patients 
deem necessary.
To clarify the mechanism of action for GA, which 
requires daily injections, and also to describe how the TEVA 
adherence program works once Brazilian patients start on 
GA, a short summary of these two topics is detailed below.
Glatiramer acetate (Copaxone®, 
TEVA Pharmaceutical, Israel)
GA was developed in the 1960s, as a standard mixture of 
synthetic polypeptides with four amino acids: L-alanine, 
L-glutamine, L-lysine and L-tyrosine. The drug was dis-
covered during an attempt to isolate the antigen responsible 
for experimental allergic encephalomyelitis (EAE), which is 
the animal model for MS (Wolinsky 1995). It turned out that 
GA was not capable of inducing EAE and, furthermore, had 
a suppressive effect on the animal disease. Several clinical 
trials with long-term follow-up have shown that GA is an 
effective treatment for MS (Ford et al 2006). The mecha-
nism of action for GA is unique among the drugs at present 
approved for MS treatment: rather than having any speciﬁ  c 
and direct anti-inﬂ  ammatory effect through inhibition of Th-1 
lymphocytes, GA promotes a shift to an anti-inﬂ  ammatory 
environment by activating Th-2 lymphocytes (Young 2002). 
Maintenance of this anti-inﬂ  ammatory shift is obtained by 
daily subcutaneous injections of GA.
Among the adverse reactions with GA, the most 
frequent are redness, itching, pain, and swelling at the 
injection site. These reactions are usually mild and sel-
dom require professional treatment. Some patients report 
a short-term reaction immediately after injecting GA. 
Table 1 Possible factors inﬂ  uencing adherence to immunomodulatory 
treatment for multiple sclerosis
Reasons for not adhering  Patient’s justiﬁ  cation
Long periods of remission Idea of being cured
Injections Fear or discomfort with needles
Occurrence or fear of side effects Previous experience or 
information from other patients
Hopelessness and resignation Idea of a disease without cure
Lack of motivation and/or 
knowledge
Reasons for treatment were not 
explained
Unmet expectations from 
treatment
Lack of improvement of sequelae 
or new relapse
Search for other forms of 
treatment
Inﬂ  uence from family and friends
Several consultations searching for 
another diagnosis and denial of the 
disease
Conﬂ  icting information from 
health care providersPatient Preferences and Adherence 2008:2 43
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This reaction may involve ﬂ  ushes, chest tightness or pain, 
tachycardia, or breathing trouble. These symptoms gener-
ally appear within minutes of an injection, are short-lived 
and go away by themselves without further problems. 
Despite the short duration, the so-called immediate post-
reaction can be very distressing for patients. However, full 
awareness among patients that such a reaction is possible 
seems to decrease discontinuation if the reaction occurs 
(Fiore and Fragoso 2005). Severe skin reactions to GA 
injections have recently been reported in some patients 
(Frohman et al 2004). Although infrequent, such skin reac-
tions (including lipoatrophy, necrosis, and erythema nodo-
sum) are severe enough to require discontinuation of GA 
treatment (Frohman et al 2004; Thouvenot et al 2007).
PACO – The Assistance Program 
for Copaxone®
This assistance program was created in June 2003, and 
every Brazilian patient with a medical prescription for 
Copaxone® can enroll via a free phone call to the central 
PACO system, in TEVA Pharmaceutical, São Paulo. In 
the initial phone call, the patient is registered in the pro-
gram and receives detailed information about the medica-
tion, including: storage, transportation, the importance 
of adherence, possible side effects, alternative injection 
sites, and special guidance to avoid local reactions at the 
injection site.
The patient receives at home, free of any charge, an insu-
lated bag for carrying the medication, a written guide and DVD 
on how to perform the injections, a box for used needles and 
syringes, a gel bag for soothing the area where the injection is 
made, the Autoject® (Owen Munford Ltd., Oxford, England) 
self-applicator, and printed material regarding MS.
All patients will thereafter receive a phone call every 
fortnight for 90 days and every 3 months after this initial 
90-day period. Extra phone calls from PACO nurses 
and from the patients to the central system are made as 
deemed necessary (for example, in cases of side effects). 
Visits by nurses to patients’ homes can be organized if 
necessary. The patients are also regularly reminded about 
the importance of attending medical consultations with 
their neurologist.
Workshops on a variety of subjects (for example, nutri-
tion, art and crafts, etc) are regularly organized in different 
cities in Brazil.
Nurses working at reference centers for MS can be speciﬁ  -
cally trained through PACO to attend to the needs of patients 
living in the area covered by that particular MS service.
Methods
Data from all Brazilian patients enrolled in the PACO pro-
gram between June 2003 and December 2006 were assessed. 
Their registration included gender, age and educational level 
attained. Data on discontinuation of GA treatment were 
obtained for the period from January 2006 to December 
2006. All patients discontinuing treatment with GA gave 
their own reasons for stopping taking the medication, and 
there was no record of medical reasons in PACO for such 
discontinuation. This program is directed towards patients, 
and medical doctors do not contact it unless they speciﬁ  cally 
want to do so.
Statistical data were analyzed by the Software Minitab 
14®, using chi-square and relative risk for assessment of 
treatment interruption. Signiﬁ  cance level was established 
as p   0.05.
Results
A total of 1131 patients were fully registered within the 
program between June 2003 and December 2006. The 
demographic characteristics of these patients are presented 
in Table 2. In summary, there were 289 males (26%) and 842 
females (74%), aged between 9 and 79 years.
A total of 113 patients (10%) stopped their treatment 
with GA, for a variety of reasons that are detailed in Table 3. 
Eight patients were excluded from the data because they died 
during the study period.
The main reason for stopping the treatment was medical 
advice (53 cases; 47% of the total number of stopped 
treatments). No information was given on possible switching 
of therapy to another immunomodulatory agent, since PACO 
does not record either the medical reports on patient care or 
the follow-up for patients who are not taking GA. A group of 
Table 2 Demographic characteristics of patients undergoing treat-
ment for multiple sclerosis with glatiramer acetate in Brazil
Gender Number of patients Percentage of total
Male 289 26%
Female 842 74%
Age group (years)
9–20 85 8%
21–30 220 19%
31–40 333 29%
41–50 288 25%
51–60 168 15%
61–70 34 3%
70–79 3  1%Patient Preferences and Adherence 2008:2 44
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20 patients (18% of all the discontinuations) explained that 
ceasing to take GA was their own decision, mainly because 
they did not perceive any improvement with this treatment. A 
group of 35 patients (31% of all the discontinuations) stopped 
taking GA due to adverse events, none of them recorded 
as serious. Among this group who stopped taking GA due 
to adverse events, 9 patients mentioned systemic reactions 
immediately after the injection, and 8 patients could not 
tolerate the reactions at the injection site. The remaining 18 
patients mentioned a variety of symptoms that might or might 
not have been related to GA, since some of them appeared 
to be related to MS itself (for example, fatigue).
There was no correlation between gender, age, years of 
formal education, and stopping the treatment (Table 4). The 
largest single group of patients who stopped their treatment 
did so after receiving between 6 and 12 months of GA therapy 
(27% of the discontinuations for that period of treatment). 
Relative risk assessment showed a 3.42 times higher chance 
of interrupting treatment in this period of 6–12 months of 
GA treatment, as shown in Table 5.
Discussion
Adherence to treatment among MS cases is a challenge for 
all healthcare providers. This is a chronic and disabling 
disease, for which no cause and/or cure are known. Despite 
encouraging results with immunomodulatory treatment, the 
main goal of this therapy is to delay disability in patients who 
still respond to this immunological approach. The simple 
knowledge that the treatment is not curative and consists 
of injections with a variety of side effects may discourage 
patients from persisting with the treatment. A large survey 
among neurologists treating over 2500 MS patients showed 
that “forgetting to take the injection” was the main reason 
for non-adherence to treatment (Devonshire et al 2006). The 
present work did not deal with the matter of non-adherence 
to the occasional injection but, rather, took discontinuation 
of treatment to be the main objective of this investigation.
The medical reasons for stopping the treatment, which 
were the main motive for discontinuation of GA among 
Brazilian patients, cannot be discussed here because PACO 
does not record such information. A smaller, but still consider-
able percentage of the patients stopped their treatment because 
of personal reasons, and most discontinuations occurred soon 
after the frequency of the phone call program had gone down 
to 1 call every 3 months. Education for patients and caregivers 
is essential for them to understand the need to comply with the 
scheme for the proposed medication, as well as for them to 
have realistic expectations from the treatment. As shown ear-
lier, in Table 1, most reasons for stopping the treatment were 
related to the lack of proper knowledge about the disease and 
Table 3 Number of patients discontinuing treatment with 
glatiramer acetate and their motives for this interruption
Reason for discon-
tinuation of treat-
ment
Number of 
patients
Percentage of 
the number of 
patients who 
interrupted 
(n = 113)
Percentage of 
total number 
of patients 
(n = 1131)
Medical conduct 53 47% 5%
Patient’s own choice 20 18% 2%
Non-serious adverse 
event
18 16% 2%
Immediate reaction 
post-injection
98 %  1%
Reaction in the site of 
injection
87 %  1%
Pregnancy 4 4%  1%
Hematopoietic stem 
cell transplantation
11 %  1%
Table 4 Period of treatment with glatiramer acetate between June 2003 and December 2006, and discontinuations of therapy; the 
only signiﬁ  cant p value was observed for the period 6–12 months of glatiramer acetate therapy
Period of 
use
Total number of 
patients (n = 1131)
Percentage of total 
number of patients
Number of patients who interrupted 
treatment (n = 113)
Percentage of patients in that period 
who interrupted treatment
Up to 6 
months
233 21% 22 9%
6 to 12 
months
131 12% 35 27% (p   0.001)
One year 167 15% 23 14%
Two years 330 29% 23 7%
Three years 236 21% 10 4%
Four years 34 3% - -Patient Preferences and Adherence 2008:2 45
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the excessive expectations. All pharmaceutical companies that 
are currently commercializing immunomodulatory drugs for 
MS typically provide a speciﬁ  c support program for patients 
taking their drugs. These programs are aimed at the needs 
of speciﬁ  c countries with different cultures, socioeconomic 
backgrounds and educational levels.
Based upon previous experience with early discontinu-
ation of immunomodulatory treatment, typically within 6 
months of starting (Tremlett and Orger 2003), most programs 
for patients appear to concentrate their efforts in this initial 
period. The US Copaxone® program, with a lower number 
of phone calls, has recently reported high rates of discon-
tinuations of GA treatment within 3 months of starting the 
injections (Parker and Beach 2006, 2007). The approach in 
the US program has been to attempt to identify “high risk” 
patients and concentrate the efforts on this group. The results 
from the present study showed that discontinuation was most 
likely to occur over a longer period of 6–12 months, when 
the number of phone calls to patients had decreased. No 
gender, years of schooling, or age-related groups at risk were 
identiﬁ  ed, and therefore it was not possible to consider that 
a particular subgroup of patients is at “higher” or “lower” 
risk. Based on the results obtained here, the PACO program 
for MS patients in Brazil is now considering an increased 
number of phone calls and visits for all patients, during the 
whole ﬁ  rst year of treatment.
The proﬁ  les of the side effects of IFNβ (O’Rourke and 
Hutchinson 2005) and GA (Parker and Beach 2006, 2007) 
are reported to be an important reason for early discontinua-
tion of treatment. Again, this was not observed in the present 
study with GA, in which only 4% of the whole group of 
patients discontinued their treatment because of side effects. 
Healthcare support for patients has been rated as an important 
factor for adherence to GA treatment (Fraser et al 2001), and 
it is possible that the low levels of discontinuation in Brazil 
are related to this special program. In addition, the personal 
and special attention given to every case by a multidisci-
plinary team, which is typical of the university reference 
centers, may also be reﬂ  ected in the high rate (90%) of 
adherence to long-term treatment with GA.
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